siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice
- 21 July 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (553)
- https://doi.org/10.1126/scitranslmed.aay1063
Abstract
Atherosclerotic lesional macrophages express molecules that promote plaque progression, but lack of mechanisms to therapeutically target these molecules represents a major gap in translational cardiovascular research. Here, we tested the efficacy of a small interfering RNA (siRNA) nanoparticle (NP) platform targeting a plaque-destabilizing macrophage molecule-Ca2+/calmodulin-dependent protein kinase gamma (CaMKII gamma). CaMKII gamma becomes activated in advanced human and mouse plaque macrophages and drives plaque necrosis by suppressing the expression of the efferocytosis receptor MerTK. When macrophage-targeted siCamk2g NPs were administered to Western dietfed Ldlr(-/-) mice, the atherosclerotic lesions showed decreased CaMKII gamma and increased MerTK expression in macrophages, improved phagocytosis of apoptotic cells (efferocytosis), decreased necrotic core area, and increased fibrous cap thickness-all signs of increased plaque stability-compared with mice treated with control siRNA NPs. These findings demonstrate that atherosclerosis-promoting genes in plaque macrophages can be targeted with siRNA NPs in a preclinical model of advanced atherosclerosis.Funding Information
- National Institutes of Health (HL127464)
- National Institutes of Health (HL132412)
- National Institutes of Health (HL145228)
- Brigham and Women’s Hospital (122829)
This publication has 46 references indexed in Scilit:
- Near Infrared Imaging and Photothermal Ablation of Vascular Inflammation Using Single‐Walled Carbon NanotubesJournal of the American Heart Association, 2012
- Therapeutic siRNA silencing in inflammatory monocytes in miceNature Biotechnology, 2011
- siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipidsJournal of Lipid Research, 2011
- Macrophages in the Pathogenesis of AtherosclerosisCell, 2011
- RNA interference in the clinic: challenges and future directionsNature Reviews Cancer, 2010
- A Light‐Activated Theranostic Nanoagent for Targeted Macrophage Ablation in Inflammatory AtherosclerosisSmall, 2010
- Matrix-Specific Protein Kinase A Signaling Regulates p21-Activated Kinase Activation by Flow in Endothelial CellsCirculation Research, 2010
- The promises and pitfalls of RNA-interference-based therapeuticsNature, 2009
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesProceedings of the National Academy of Sciences of the United States of America, 2008
- Matrix-specific p21-activated kinase activation regulates vascular permeability in atherogenesisThe Journal of cell biology, 2007